CRP and COVID-19: Although in the absence of a control group, a definite statement is still not possible, we can postulate that mAbs treatment may have a high clinical significance in patients with negative anti-spike serology as an increase in CRP and other pro-inflammatory markers at baseline has been widely associated with worse outcome in patients with COVID-19 [22,23].